No Data
No Data
No Data
No Data
No Data
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and
GlobeNewswireApr 24 16:30 ET
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the
GlobeNewswireApr 18 16:30 ET
Is MeiraGTx Holdings (NASDAQ:MGTX) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Simply Wall StApr 4 06:01 ET
RBC Capital Reiterates Outperform on MeiraGTx Hldgs, Maintains $11 Price Target
RBC Capital analyst Luca Issi reiterates MeiraGTx Hldgs (NASDAQ:MGTX) with a Outperform and maintains $11 price target.
BenzingaMar 15 12:23 ET
MeiraGTx Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 74.88% RBC Capital → $11 Reiterates Outperform → Outperform 08/11/2023 74.88% RBC Capital $13 →
BenzingaMar 15 12:21 ET
Buy Rating Affirmed: Meiragtx Holdings' Promising Pipeline and Strategic Partnerships Set Stage for Growth
TipRanksMar 15 07:46 ET
No Data
No Data